Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Richard Holland and Paul Billings


The Pistoia Alliance has hired Richard Holland to serve as its executive director of operations.

Holland comes to Pistoia after working for bioinformatics consultancy Eagle Genomics for six years. He will begin his new role at Pistoia in June this year, leading a team focused on building and delivering a portfolio of diverse and complex initiatives for the alliance.

Omicia has hired Paul Billings as its chief medical officer and to serve on its scientific advisory board.

Prior to joining Omicia, Billings was CMO at Life Technologies, now owned by Thermo Fisher Scientific. Before that he was founded and served as acting director and chief scientific officer of the Genomic Medicine Institute at El Camino Hospital. He's also served as president, CEO, and director of Cellective Dx and is one of the founder's of CBR Systems and GeneSage. Other positions he's held include senior vice president and senior geneticist at Laboratory Corporation of America Holdings.

In addition to his new position at Omicia, Billings currently a director at Trovagene and CollabRx. He also serves on the US Food and Drug Administration's SAB, the Genomic Medicine Advisory Committee at the Department of Veterans Affairs, and the National Academy of Sciences Institute of Medicine’s Roundtable on Genomics.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.